{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:59:08Z","timestamp":1770983948540,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.clinthera.2010.01.006","type":"journal-article","created":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T04:27:14Z","timestamp":1266467234000},"page":"146-160","source":"Crossref","is-referenced-by-count":18,"title":["Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers"],"prefix":"10.1016","volume":"32","author":[{"given":"David","family":"Vaughan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Speed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Medve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.01.006_bib1","series-title":"Migraine\u2014A Market Focus","year":"2004"},{"key":"10.1016\/j.clinthera.2010.01.006_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1526-4610.2001.041007646.x","article-title":"Prevalence and burden in the United States: Data from the American Migraine Study II","volume":"41","author":"Lipton","year":"2001","journal-title":"Headache."},{"key":"10.1016\/j.clinthera.2010.01.006_bib3","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2165\/00003495-200060060-00003","article-title":"Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy","volume":"60","author":"Tfelt-Hansen","year":"2000","journal-title":"Drugs."},{"key":"10.1016\/j.clinthera.2010.01.006_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ana.10786","article-title":"Defeating migraine pain with triptans: A race against the development of cutaneous allodynia","volume":"55","author":"Burstein","year":"2004","journal-title":"Ann Neurol."},{"key":"10.1016\/j.clinthera.2010.01.006_bib5","first-page":"209","article-title":"Pharmacology of migraine","volume":"34","author":"Raskin","year":"1990","journal-title":"Prog Drug Res."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.01.006_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1526-4610.1990.hed30s1005.x","article-title":"The pharmacology of current anti-migraine drugs","volume":"30","author":"Peroutka","year":"1990","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2010.01.006_bib7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1460-9568.1996.tb01583.x","article-title":"Activation of meningeal 5-HT2B receptors: An early step in the generation of migraine headache?","volume":"8","author":"Schmuck","year":"1996","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.clinthera.2010.01.006_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1533-2500.2004.04002.x","article-title":"NO pain: Potential roles of nitric oxide in neuropathic pain","volume":"4","author":"Levy","year":"2004","journal-title":"Pain Pract."},{"key":"10.1016\/j.clinthera.2010.01.006_bib9","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1136\/jnnp.2004.050633","article-title":"Occipital activation in glyceryl trinitrate induced migraine with visual aura","volume":"76","author":"Afridi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.006_bib10","first-page":"28","article-title":"Nitric oxide theory of migraine","volume":"5","author":"Thomsen","year":"1998","journal-title":"Clin Neurosci."},{"key":"10.1016\/j.clinthera.2010.01.006_bib11","series-title":"Nitric Oxide Biology and Pathobiology","year":"2000"},{"key":"10.1016\/j.clinthera.2010.01.006_bib12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1023\/A:1024800512790","article-title":"The role of nitric oxide in vascular headache","volume":"25","author":"van der Kuy","year":"2003","journal-title":"Pharm World Sci."},{"key":"10.1016\/j.clinthera.2010.01.006_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s005990050033","article-title":"Modulation of nitric oxide synthase by nitric oxide donor compounds in migraine","volume":"28","author":"Martelleti","year":"1998","journal-title":"Int J Clin Lab Res."},{"key":"10.1016\/j.clinthera.2010.01.006_bib14","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/j.1468-1331.2006.01509.x","article-title":"Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients","volume":"13","author":"Rejdak","year":"2006","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.clinthera.2010.01.006_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2005.03.026","article-title":"Effects of acute and chronic restraint stress on nitroglycerin-induced hyperalgesia in rats","volume":"383","author":"Costa","year":"2005","journal-title":"Neurosci Lett."},{"key":"10.1016\/j.clinthera.2010.01.006_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0006-8993(98)00147-4","article-title":"Rapid development of nitric oxide-induced hyperalgesia depends on an alternate to the cGMP-mediated pathway in the rat neuropathic pain model","volume":"792","author":"Inoue","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.clinthera.2010.01.006_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2005.11.029","article-title":"Nitric oxide and its modulators in chronic constriction injuryinduced neuropathic pain in rats","volume":"530","author":"Naik","year":"2006","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.clinthera.2010.01.006_bib18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/0264-6021:3570593","article-title":"Nitric oxide synthases: Structure, function and inhibition","volume":"357","author":"Alderton","year":"2001","journal-title":"Biochem J."},{"key":"10.1016\/j.clinthera.2010.01.006_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1468-2982.1998.1801027.x","article-title":"Nitric oxide synthase inhibition: A new principle in the treatment of migraine attacks","volume":"18","author":"Lassen","year":"1999","journal-title":"Cephalalgia."},{"key":"10.1016\/j.clinthera.2010.01.006_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0140-6736(98)01079-4","article-title":"Effect of inhibition of nitric oxide synthase on chronic tension-type headache: A randomised crossover trial","volume":"353","author":"Ashina","year":"1999","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2010.01.006_bib21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00001756-199802160-00002","article-title":"Nitric oxide mediates behavioral signs of neuropathic pain in an experimental rat model","volume":"9","author":"Yoon","year":"1998","journal-title":"Neuroreport."},{"key":"10.1016\/j.clinthera.2010.01.006_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0028-3908(97)00201-3","article-title":"Effects of selective inhibitors of neuronal nitric oxide synthase on carrageenan-induced mechanical and thermal hyperalgesia","volume":"37","author":"Handy","year":"1998","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.clinthera.2010.01.006_bib23","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.bjp.0702508","article-title":"Effects of intrathecal administration of nitric oxide synthase inhibitors on carrageenan-induced thermal hyperalgesia","volume":"126","author":"Osborne","year":"1999","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.clinthera.2010.01.006_bib24","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1001\/jama.284.23.3043","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"284","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.01.006_bib25","series-title":"Pharmacokinetics","first-page":"451","author":"Gibaldi","year":"1982"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181000007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181000007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:51:55Z","timestamp":1544662315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181000007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S014929181000007X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.01.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}